首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1395542

癌症抗體聯合治療的全球市場：市場機會和臨床試驗分析（2028）

Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028

出版日期: 2023年12月01日 | 出版商:

KuicK Research | 英文 1500 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

本報告分析結果及摘要如下：

全球癌症抗體合併治療市場機會：到 2028 年將達到 400 億美元以上
已核准上市的癌症抗體聯合療法市場分析：超過65種抗體的聯合療法
臨床試驗中癌症抗體合併療法的見解：超過 450 種抗體的合併療法
有關已批准的聯合療法的專利、價格和劑量的見解
全球癌症抗體合併療法臨床試驗分析：依公司、適應症及分期（依階段）
全球抗體聯合療法市場趨勢：按地區和適應症劃分

分析中包含的組合

核准的抗體和抗體聯合療法
已核准的抗體和小分子抑制劑的聯合療法
已核准的抗體和免疫調節劑的聯合療法
已核准的抗體和化療的聯合治療
核准的抗體和聯合療法
目前臨床試驗：雙特異性抗體聯合療法、癌症疫苗、細胞療法和放射療法

近年來，隨著抗體聯合療法的出現，癌症治療領域發生了典範轉移。這是一種動態方法，結合了針對特定分子的抗體的精確性與不同抗體的協同效應。透過將不同類型的單株抗體與其他治療藥物結合，可以同時靶向涉及癌症發展的許多途徑，從而可能產生相加或協同效應。理論上，抗體聯合療法有助於限制多餘的毒性，並且缺乏藥物動力學（PK）相互作用，使得抗體聯合療法成為癌症治療的可行選擇，這是一種非常合適的方法。

將抗體與其他治療藥物結合的假說最早於20 世紀90 年代末提出，當時研究人員和科學家合作解決癌症惡性腫瘤中觀察到的抗藥性菌株的出現和逃脫機制。單株抗體的臨床前測試（單株抗體）與化療、放療和其他治療藥物合併使用。這些研究的主要目的是擴大單株抗體的治療指數和潛力。在臨床前研究中，已觀察到抗體組合具有諸如提高治療效率、降低毒性、延遲治療和抗藥性起效以及減少劑量等優點。

化學療法和放射療法等傳統療法有可能損害健康細胞，但抗體聯合療法的出現徹底改變了標靶醫學的模式。目前，多種抗體聯合療法如Phesgo、赫賽汀和帕妥珠單抗、雷莫蘆單抗和多西他賽、阿特珠單抗、貝伐單抗和化療、阿特珠單抗和貝伐單抗、伊匹單抗和納武單抗等已被FDA、EMA、NICE等批准用於多種癌症的治療。它一直。

在癌症治療領域，抗體聯合治療領域的初步臨床開發重點是抗PD-1、抗CTLA-4、抗PD-L1單株抗體的打造(mAb)聯合療法。化療以及針對血管內皮生長因子受體(VEGFR)和血小板源性生長因子受體(PDGFR)的各種治療已被用作多種癌症的一線治療，包括晚期實體瘤和血液癌。在利用單株抗體與口服小分子多激□抑制劑聯合使用的潛力方面，已經觀察到了改進。中國浙江大學正在進行一項臨床試驗，以評估抗 PD-1 抗體與多激□抑制劑多納非尼聯合治療方案的安全性和有效性。

另一家中國製藥公司Chia Tai Tianqing Pharmaceutical Group推出了抗PD-1抗體penplimab與多靶點受體TKI安羅替尼的聯合療法，用於治療肝細胞癌（HCC）患者。我報道過。本研究的主要目的是評估合併療法作為輔助療法的療效。該研究為隨機、雙盲、安慰劑對照、多中心 3 期研究，預計於 2023 年 5 月開始，於 2026 年 12 月完成。

迄今為止，用於癌症治療的抗體聯合療法的臨床管線主要由CTLA-4、PD-1、PD-L1等免疫檢查點抑制劑、PP2A抑制劑、CDK4/6抑制劑、單株抗體組成標靶 HER 2、TIGIT mAb、雙特異性抗體、CAR-T 細胞療法和抗體/藥物組合。我們當然可以期望在不久的將來見證用於治療癌症惡性腫瘤的創新抗體聯合療法，製藥業日益增長的興趣以及 FDA 對新型聯合療法的指定推廣就證明了這一點。例如，2023年8月，Agenas 因其用於治療結直腸癌患者的創新抗體組合 botencilimab (AGEN1181) 和 balstilimab (AGEN2034) 獲得快速通道指定。

隨著癌症類型數量以驚人的速度增加，世界各地的癌症患者都在尋求更好的治療方法，這些治療方法除了治療之外還能帶來意想不到的益處，越來越需要開發創新的抗體組合療法。此外，利用抗體聯合療法領域將涉及各種利益相關者，包括Pfizer、Bristol-Myers Squibb、AstraZeneca、Daiichi Sankyo、Agenus、Novartis、Celldex Therapeutics、Merck等製藥和生物技術公司，這一趨勢正在不斷增長。在目前的市場情況下，抗體藥物組合市場的未來是充滿希望的，臨床試驗數量的增加、研發活動的增加以及各利益相關者對該領域的參與都證明了這一點，預計將擴大。

AbbVie
Adagene
Agenus
Akeso Biopharma
Amgen
AstraZeneca
BeiGene
Biocad
BioInvent International
Bio-Thera Solutions
Boehringer Ingelheim
Bristol-Myers Squibb
Concentra Biosciences
Daiichi Sankyo Company
Eli Lilly and Company
Eucure Biopharma
Genentech
Genmab
GSK
ImmunoGen
Innovent Biologics
Janssen Research & Development
Jiangsu Hengrui Medicine Co.
LaNova Medicines Limited
Lepu Biopharma
MacroGenics
Merck
Merus
NGM Biopharmaceuticals
Novartis
Pfizer
Regeneron Pharmaceuticals
Roche
Seagen
Shanghai Henlius Biotech
Shanghai Junshi Biosciences
Sinocelltech
Symphogen
UCB
Xencor

簡介目錄圖表

“Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028” Report Findings & Highlights:

Global Cancer Antibody Combinations Market Opportunity: > USD 40 Billion By 2028
Insight On Approved Cancer Antibody Combinations In Market: > 65 Antibodies Combinations
Insight On Cancer Antibody Combinations In Clinical Trials: > 450 Antibodies Combinations
Patent, Pricing, & Dosage Insight On Approved Combinations
Global Cancer Antibody Combinations Clinical Trials Insight By Company, Indication & Phase
Global Antibody Combinations Market Development by Region & Indications

Combinations Included In Report:

Approved Antibody - Antibody Combinations
Approved Antibody - Small Molecule Inhibitors Combinations
Approved Antibody - Immunomodulatory Agents Combinations
Approved Antibody - Chemotherapy Combinations
Approved Antibody - Mixed Combinations
Ongoing Clinical Trials Combination With Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Radiotherapy

In recent years, the landscape of cancer therapeutics has witnessed a paradigm shift with the emergence of antibody combination therapies, a dynamic approach that intertwines the precision of antibodies to target specific molecules with the synergistic benefits of different types of antibodies. By merging different types of monoclonal antibodies with other therapeutic agents, numerous pathways that are involved in the pathogenesis of cancer may be targeted simultaneously, thereby, possibly leading to additive or else synergistic effects. Theoretically, the combinations of antibodies are very suitable approach that can be employed for the treatment of cancer modalities because of the fact that the antibody combination therapy aids to limit overlapping toxicity along with lack of pharmacokinetic (PK) interactions.

The hypothesis of combining antibodies with other therapeutic agents began in the late 1990s when the researchers together with scientists amplified the preclinical testing that includes a combinations of monoclonal antibodies (mAb) with chemotherapy, radiotherapy or any other therapeutic agents in order to address the occurrence of drug resistant strains or the escape mechanism for observed in cancer malignancies. The main purpose of these investigations was to expand the therapeutic index as well as the potential of mAbs. Advantages such as amended efficiency, diminished toxicities, delayed development of therapy or drug resistances in addition dose reduction were observed in the preclinical studies that come along with antibody combinations.

In dichotomy with the conventional treatments such as chemotherapy and radiotherapy, which clenches the possibility to damage healthy cells, with the arrival of antibody combination therapies has transformed the landscape of targeted medicine. As of now, multiple antibody combination therapies such as Phesgo, Herceptin with Perjeta, Ramucirumab with docetaxel, atezolizumab, Bevacizumab with chemotherapy, atezolizumab and bevacizumab, and ipilimumab and nivolumab etc have been approved by the FDA, EMA, NICE and others for the treatment of diverse type of cancers.

In the realm of cancer therapy, the preliminary clinical development for the domain of antibody combinations were focused on creating anti-PD-1, anti-CTLA-4 and anti-PD-L1 monoclonal antibody (mAb) combinations, there has been modern improvement observed in harnessing the potential of mAb in conjugation with chemotherapy or with various oral small molecule multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) or platelet derived growth factor receptor (PDGFR) as the first-line treatment for multiple types of cancer like advanced solid tumors, hematological cancer, etc. Zhejiang University based in China is conducting clinical studies in which the combination of anti-PD-1 antibody with Donafenib, multikinase inhibitor, is ongoing to evaluate the safety and efficacy of the treatment regimen.

Another pharmaceutical company based in China, Chia Tai Tianqing Pharmaceutical Group reported another combination of anti-PD-1 antibody, Penpulimab with multi targeted receptor TKI, Anlotinib for the treatment of patients suffering from hepatocellular cancer (HCC). The primary goal of this study is to assess the effectiveness of combined treatment regimen for adjuvant therapy. It is a randomized, double-blind, placebo-controlled, multicenter phase 3 study which was initiated in May 2023 and is expected to be complete by December 2026.

Hitherto, the clinical pipeline for the domain of antibody combination therapy for treating cancer modalities majorly consists of immune checkpoint inhibitors, such as CTLA-4, PD-1 and PD-L1, PP2A inhibitors, CDK4/6 inhibitors, mAbs targeting HER 2, TIGIT mAbs, bispecific antibodies, CAR T cell therapies, antibody drug conjugates, and others. It is expected that the imminent years will certainly witness innovative antibody combinations for the treatment of cancer malignancies as evident from augmenting interest in pharmaceutical sectors and fostering FDA designations to novel combination therapy. For instance, in August 2023, Agenus was granted the Fast Track Designation for its innovative antibody combination, botensilimab (AGEN1181) and balstilimab (AGEN2034) for the treatment of colorectal cancer patients.

With the increasing prevalence of cancer types at an alarming gait urges the need to develop better as well as innovative antibody combination therapies which could provide cure in addition to anticipation amidst the populace suffering from cancer across the globe. Furthermore, an inclining market trend towards utilizing the realm of antibody combination has been observed due to involvement of various stakeholders from pharmaceutical and biotech companies such as Pfizer, Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo, Agenus, Novartis, Celldex Therapeutics and Merck. With the current market scenario, the future of the antibody combination market looks promising and is expected to multiple further as evident from the growing clinical trials, rising research and development and involvement of various stakeholders in the domain.

1. Introduction to Cancer Antibody Combinations

1.1. History, Development & Evolution
1.2. Approved Cancer Antibody Combinations

2. Need of Antibody Combinations

3. Global Cancer Antibody Combinations Market & Clinical Development Insight

3.1. Current Market Scenario
3.2. Future Outlook

4. Global Antibody Combinations Market Insight by Region

4.1. US
4.2. China
4.3. Europe
4.4. Japan
4.5. UK
4.6. Canada
4.7. South Korea

5. Global Cancer Antibody Combinations Clinical Trials Overview

5.1. By Antibody Classification
5.2. By Breakthrough Therapy & Fast Track Status
5.3. By Company
5.4. By Country
5.5. By Indication
5.6. By Phase

6. Global Antibody Combinations Market Insight by Indication

6.1. Lung Cancer
6.2. Melanoma
6.3. Breast Cancer
6.4. Hepatocellular Cancer
6.5. Colorectal Cancer
6.6. Renal Cell Carcinoma
6.7. Lymphoma
6.8. Leukemia
6.9. Multiple Myeloma

7. Global Cancer Antibody Combinations Clinical Trials Insight By Company, Indication & Phase

7.1. Research
7.2. Preclinical
7.3. Phase-I
7.4. Phase-I/II
7.5. Phase-II
7.6. Phase-II/III
7.7. Phase-III
7.8. Preregistration
7.9. Registered

8. Approved/Marketed Cancer Antibody Combinations Clinical Trials Insight By Company, Country & Indication

9. Antibody - Antibody Combinations - Pricing, Patent & Dosing Insight

9.1. Opdivo + Yervoy
- 9.1.1. Overview & Patent Insight
- 9.1.2. Pricing & Dosage Insight
9.2. Opdualag (nivolumab & relatlimab)
- 9.2.1. Overview & Patent Insight
- 9.2.2. Pricing & Dosage Insight
9.3. Imjudo + Imfinzi
- 9.3.1. Overview & Patent Insight
- 9.3.2. Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample.

10. Antibody - Small Molecule Inhibitors Combinations - Pricing, Patent & Dosing Insight

10.1. Gazyva + Imbruvica
- 10.1.1. Overview & Patent Insight
- 10.1.2. Pricing & Dosage Insight
10.2. Imbruvica + Rituximab
- 10.2.1. Overview & Patent Insight
- 10.2.2. Pricing & Dosage Insight
10.3. Bavencio + Inlyta
- 10.3.1. Overview & Patent Insight
- 10.3.2. Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample.

11. Antibody - Immunomodulatory Agents Combinations - Pricing, Patent & Dosing Insight

11.1. Monjuvi + lenalidomide
- 11.1.1. Overview & Patent Insight
- 11.1.2. Pricing & Dosage Insight
11.2. Avastin + Interferon-alfa
- 11.2.1. Overview & Patent Insight
- 11.2.2. Pricing & Dosage Insight

12. Antibody - Chemotherapy Combinations - Pricing, Patent & Dosing Insight

12.1. Jemperli
- 12.1.1. Overview & Patent Insight
- 12.1.2. Pricing & Dosage Insight
12.2. Cyramza
- 12.2.1. Overview & Patent Insight
- 12.2.2. Pricing & Dosage Insight
12.3. Portrazza
- 12.3.1. Overview & Patent Insight
- 12.3.2. Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample.

13. Antibody - Mixed Combinations

13.1. Phesgo (Perjeta + Herceptin + hyaluronidase)
- 13.1.1. Overview & Patent Insight
- 13.1.2. Pricing & Dosage Insight
13.2. Darzalex
- 13.2.1. Overview & Patent Insight
- 13.2.2. Pricing & Dosage Insight
13.3. Empliciti
- 13.3.1. Overview & Patent Insight
- 13.3.2. Pricing & Dosage Insight

Detailed Combinations Are Mentioned in Report Sample.

14. Competitive Landscape

14.1. AbbVie
14.2. Adagene
14.3. Agenus
14.4. Akeso Biopharma
14.5. Amgen
14.6. AstraZeneca
14.7. BeiGene
14.8. Biocad
14.9. BioInvent International
14.10. Bio-Thera Solutions
14.11. Boehringer Ingelheim
14.12. Bristol-Myers Squibb
14.13. Concentra Biosciences
14.14. Daiichi Sankyo Company
14.15. Eli Lilly and Company
14.16. Eucure Biopharma
14.17. Genentech
14.18. Genmab
14.19. GSK
14.20. ImmunoGen
14.21. Innovent Biologics
14.22. Janssen Research & Development
14.23. Jiangsu Hengrui Medicine Co.
14.24. LaNova Medicines Limited
14.25. Lepu Biopharma
14.26. MacroGenics
14.27. Merck
14.28. Merus
14.29. NGM Biopharmaceuticals
14.30. Novartis
14.31. Pfizer
14.32. Regeneron Pharmaceuticals
14.33. Roche
14.34. Seagen
14.35. Shanghai Henlius Biotech
14.36. Shanghai Junshi Biosciences
14.37. Sinocelltech
14.38. Symphogen
14.39. UCB
14.40. Xencor

簡介目錄圖表

List of Figures

Figure 1-1: Developmental Milestones for Antibody Combinations
Figure 2-1: Comparison of Conventional Therapies v/s Antibody Combination Therapy
Figure 2-2: Need of Antibody Combinations
Figure 2-3: Different Combinations of Antibodies with Other Therapeutic Agents
Figure 2-4: Expected Antibody Combinations
Figure 3-1: Global - Cancer Antibody Combination Market Opportunity (US$ Billion), 2023 - 2028
Figure 3-2: Antibody Combination Market - Prominent Regions
Figure 3-3: Aspects of Current Antibody Combinations Market
Figure 3-4: Future Characteristics of Antibody Combinations Market
Figure 4-1: COMBI-i Phase III Study - Initiation & Completion Years
Figure 4-2: CONTACT-01 Phase III Study - Initiation & Completion Years
Figure 4-3: NCT05800015 Phase II//III Study - Initiation & Completion Years
Figure 4-4: MagnetisMM-4 Phase II Study - Initiation & Completion Years
Figure 4-5: DREAMM 6 Phase I/II Study - Initiation & Completion Years
Figure 4-6: NCT04421352 Phase I Study - Initiation & Completion Year
Figure 4-7: NCT05867121 Phase I Study - Initiation & Completion Year
Figure 4-8: NCT06054477 Phase I/II Study - Initiation & Completion Year
Figure 4-9: NCT04868877 Phase I/II Study - Initiation & Completion Year
Figure 4-10: NCT05867121 Phase I Study - Initiation & Completion Year
Figure 4-11: NCT06038578 Phase II Study - Initiation & Completion Year
Figure 4-12: DESTINY-Breast01 Phase II Study - Initiation & Completion Year
Figure 4-13: BI-1607 & Trastuzumab Phase I/II Study - Initiation & Completion Year
Figure 4-14: Myechild01 Phase III Study - Initiation & Completion Year
Figure 4-15: GS-9911 & Zimberelimab Phase I Study - Initiation & Completion Year
Figure 4-16: EGIA-002 Phase II Study - Initiation & Completion Year
Figure 4-17: TUC1PI-01 Phase I/II Study - Initiation & Completion Year
Figure 4-18: TUC1PI-01 Phase I/II Study - Initiation & Completion Year
Figure 4-19: LEAP-008 Phase III Study - Initiation & Completion Year
Figure 4-20: VOLGA Phase III Study - Initiation & Completion Year
Figure 4-21: MarkV-01 Phase I Study - Initiation & Completion Year
Figure 5-1: Global - Cancer Antibody Combinations Clinical Trials By Antibody Classification, 2023 till 2028
Figure 5-2: Global - Cancer Antibody Combinations Clinical Trials By Priority Status, 2023 till 2028
Figure 5-3: Global - Cancer Antibody Combinations Clinical Trials By Company, 2023 till 2028
Figure 5-4: Global - Cancer Antibody Combinations Clinical Trials By Country, 2023 till 2028
Figure 5-5: Global - Cancer Antibody Combinations Clinical Trials By Indication, 2023 till 2028
Figure 5-6: Global - Cancer Antibody Combinations Clinical Trials By Phase, 2023 till 2028
Figure 6-1: Lung Cancer - Approved Antibody Combinations
Figure 6-2: Cemiplimab & Fianlimab Phase II/III Study - Initiation & Completion Year
Figure 6-3: Daratumumab, Nivolumab & KRAS vaccine Phase II Study - Initiation & Completion Year
Figure 6-4: Lung Cancer - Clinical Pipeline of Antibody Combinations
Figure 6-5: Melanoma - Approved Antibody Combinations
Figure 6-6: NCT05608291 Phase III Study - Initiation & Completion Year
Figure 6-7: OrienX010-II-11 Phase I Study - Initiation & Completion Year
Figure 6-8: MM1636 Phase I/II Study - Initiation & Completion Year
Figure 6-9: Breast Cancer - Approved Antibody Combinations
Figure 6-10: Trastuzumab & Pyrotinib Phase III Study - Initiation & Completion Year
Figure 6-11: Inetetamab, Toripalimab & Paclitaxel Phase IV Study - Initiation & Completion Year
Figure 6-12: Breast Cancer - Key Player in Antibody Combination Commercial Market
Figure 6-13: Breast Cancer - Different Antibody Combination With Other Therapeutic Agents
Figure 6-14: Hepatocellular Cancer- Approved Antibody Combinations
Figure 6-15: Combination of Antibody with DEB-TACE to Treat Hepatocellular Carcinoma
Figure 6-16: Penpulimab & Anlotinib Phase III Study - Initiation & Completion Year
Figure 6-17: Collaboration of XNK Therapeutics with Global Pharma Company
Figure 6-18: Antibody Combinations - Benefits to treat Colorectal Cancer
Figure 6-19: NCT06099951 Phase II Study - Initiation & Completion Year
Figure 6-20: KEYFORM-007 Phase III Study - Initiation & Completion Year
Figure 6-21: Renal Cell Carcinoma - Approved Antibody Combinations
Figure 6-22: SillaJen & Regeneron Pharmaceuticals - Novel Approach of Combining Oncolytic Vaccinia Virus to Treat Renal Cell Carcinoma
Figure 6-23: BMC128 & Nivolumab Phase I Study - Initiation & Completion Year
Figure 6-24: Lymphoma - Approved Antibody Combinations
Figure 6-25: NCT04464798 Phase I Study - Initiation & Completion Year
Figure 6-26: Odronextamab, Lenalidomide & Rituximab Phase III Study - Initiation & Completion Year
Figure 6-27: L-DEP & PD-1 Antibody Phase III Study - Initiation & Completion Year
Figure 6-28: Collaboration of MorphoSys & Incyte, IGM Bioscience & ADC Therapeutic, 2022
Figure 6-29: Leukemia - Approved Antibody Combinations
Figure 6-30: NCT06043674 Phase II Study - Initiation & Completion Year
Figure 6-31: NP137, Venetoclax & Azacitidine Phase I/II Study - Initiation & Completion Year
Figure 6-32: Novartis - Hypothesis for Phase 3 Clinical Study
Figure 6-33: Sabatolimab & Azacitidine Phase III Study - Initiation & Completion Year
Figure 6-34: Multiple Myeloma - Approved Antibody Combinations
Figure 6-35: NCT05730036 Phase III Study - Initiation & Completion Year
Figure 6-36: Pharmaceutical Companies Conducting Phase 3 Studies for Multiple Myeloma
Figure 6-37: NCT05363111 Phase I Study - Initiation & Completion Year
Figure 9-1: Opdivo & Yervoy - Minimum Market Exclusivity Year by Region
Figure 9-2: Opdivo & Yervoy - FDA Approval Years by Indications
Figure 9-3: Opdivo & Yervoy - EMA Approval Years by Indications
Figure 9-4: US - Opdivo Cost per Unit & Supply (US$), December'2023
Figure 9-5: US - Yervoy Cost per Unit & Supply (US$), December'2023
Figure 9-6: EU - Opdivo Cost of Supply (US$), November'2023
Figure 9-7: EU - Yervoy Cost of Supply (US$), November'2023
Figure 9-8: Opdualag - Approval Years by Region
Figure 9-9: Opdualag - Minimum Market Exclusivity Year by Region
Figure 9-10: US & EU - Opdualag Cost per Supply (US$), November'2023
Figure 9-11: Imfinzi & Imjudo - Patent Expiry Years by Region
Figure 9-12: US - Imfinzi Cost per Unit & Supply (US$), November'2023
Figure 9-13: US - Imjudo Cost per Unit & Supply (US$), November'2023
Figure 9-14: EU - Imfinzi Cost per Unit & Supply (US$), November'2023
Figure 9-15: EU - Imjudo Cost per Unit & Supply (US$), November'2023
Figure 9-16: US - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 9-17: US - Padcev Cost per Unit & Supply (US$), November'2023
Figure 9-18: EU - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 9-19: EU - Padcev Cost per Unit & Supply (US$), November'2023
Figure 9-20: US - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 9-21: US - Herceptin Cost per Unit & Supply (US$), November'2023
Figure 9-22: US - Trastuzumab Biosimilar Cost per Unit & Supply (US$), November'2023
Figure 9-23: EU - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 9-24: US - Tecentriq Cost per Unit & Supply (US$), November'2023
Figure 9-25: US - Avastin Cost per Unit & Supply (US$), November'2023
Figure 9-26: US - Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$), November'2023
Figure 9-27: US - Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$), November'2023
Figure 9-28: US - Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml & 160ml (US$), November'2023
Figure 9-29: EU - Tecentriq Cost per Unit & Supply (US$), November'2023
Figure 9-30: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), November'2023
Figure 9-31: US - Perjeta Cost per Unit & Supply (US$), November'2023
Figure 9-32: US - Herceptin Cost per Unit & Supply (US$), November'2023
Figure 9-33: US - Trastuzumab Biosimilar Cost per Unit & Supply (US$), November'2023
Figure 9-34: EU - Perjeta Cost per Supply (US$), November'2023
Figure 9-35: US - Polivy Cost per Supply (US$), November'2023
Figure 9-36: US - Rituxan Cost per Unit & Supply (US$), November'2023
Figure 9-37: US - Rituximab Biosimilar Cost per Unit & Supply of 10ml (US$), November'2023
Figure 9-38: US - Rituximab Biosimilar Cost per Unit & Supply of 50ml (US$), November'2023
Figure 9-39: EU - Polivy Cost per Supply (US$), November'2023
Figure 9-40: EU - Rituximab Biosimilar Truxima Cost per Supply (US$), November'2023
Figure 10-1: US - Imbruvica Cost per Unit & Supply of 70mg (US$), November'2023
Figure 10-2: US - Imbruvica Cost per Unit & Supply of 140mg (US$), November'2023
Figure 10-3: US - Gazyva Cost per Unit & Supply (US$), November'2023
Figure 10-4: US - Imbruvica Cost per Unit & Supply of 70mg (US$), November'2023
Figure 10-5: US - Imbruvica Cost per Unit & Supply of 140mg (US$), November'2023
Figure 10-6: US - Rituxan Cost per Unit & Supply (US$), November'2023
Figure 10-7: US - Rituximab Biosimilar Cost per Unit & Supply of 10ml (US$), November'2023
Figure 10-8: US - Rituximab Biosimilar Cost per Unit & Supply of 50ml (US$), November'2023
Figure 10-9: EU - Rituximab Biosimilar Truxima Cost per Supply (US$), November'2023
Figure 10-10: US - Bavencio Cost per Unit & Supply (US$), November'2023
Figure 10-11: US - Inlyta Cost per Unit & Supply (US$), November'2023
Figure 10-12: EU - Bavencio Cost per Unit & Supply (US$), November'2023
Figure 10-13: EU - Inlyta Cost per Unit & Supply (US$), November'2023
Figure 10-14: US - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 10-15: US - Inlyta Cost per Unit & Supply (US$), November'2023
Figure 10-16: EU - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 10-17: EU - Inlyta Cost per Unit & Supply (US$), November'2023
Figure 10-18: US - Cyramza Cost per Unit & Supply (US$), December'2023
Figure 10-19: US - Tarceva Cost per Supply (US$), December'2023
Figure 10-20: EU - Cyramza Cost per Unit & Supply (US$), December'2023
Figure 10-21: US - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 10-22: US - Lenvima Cost per Unit & Supply (US$), November'2023
Figure 10-23: EU - Keytruda Cost per Unit & Supply (US$), December'2023
Figure 10-24: US - Opdivo Cost per Unit & Supply (US$), November'2023
Figure 10-25: US - Cabometyx Cost per Unit & Supply (US$), November'2023
Figure 10-26: EU - Opdivo Cost per Unit & Supply (US$), November'2023
Figure 10-27: EU - Cabometyx Cost per Unit & Supply (US$), November'2023
Figure 11-1: US - Monjuvi Cost of Supply (US$), December'2023
Figure 11-2: US - Revlimid Cost per Unit & Supply (US$), December'2023
Figure 11-3: US - Avastin Cost per Unit & Supply (US$), December'2023
Figure 11-4: US - Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$), December'2023
Figure 11-5: US - Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$), December'2023
Figure 11-6: US - Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml & 160ml (US$), December'2023
Figure 11-7: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), December'2023
Figure 12-1: US & EU - Jemperli Cost of Supply (US$), December'2023
Figure 12-2: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 12-3: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 12-4: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 12-5: US - Cyramza Cost per Unit & Supply (US$), December'2023
Figure 12-6: EU - Cyramza Cost per Unit & Supply (US$), December'2023
Figure 12-7: US - Taxotere Cost per Unit & Supply (US$), December'2023
Figure 12-8: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 12-9: US & EU - Cyramza Cost per Unit & Supply (US$), December'2023
Figure 12-10: US - Gemzar Cost of Supply (US$), December'2023
Figure 12-11: US - Infugem Cost per Unit & Supply (US$), December'2023
Figure 12-12: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 12-13: US - Vectibix Cost per Unit & Supply (US$), December'2023
Figure 12-14: US - Eloxatin Cost per Unit & Supply (US$), December'2023
Figure 12-15: US - Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$), December'2023
Figure 12-16: US - Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-17: US - Adrucil Cost per Unit & Supply (US$), December'2023
Figure 12-18: US - Fluorouracil Cost per Unit & Supply (US$), December'2023
Figure 12-19: US - Cyclophosphamide Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-20: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml, & 500mg/ml (US$), December'2023
Figure 12-21: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Dose 200mg/ml (US$), December'2023
Figure 12-22: US - Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$), December'2023
Figure 12-23: US - Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$), December'2023
Figure 12-24: US - Adriamycin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-25: US - Adriamycin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-26: US - Doxorubicin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-27: US - Doxorubicin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-28: US - Vincristine Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-29: US - Toposar Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-30: US - Etoposide Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-31: US - Etoposide Cost per Unit & Supply of Oral Capsule (US$), December'2023
Figure 12-32: US - Prednisone Cost per Unit & Supply of 1mg/ml Oral Solution (US$), December'2023
Figure 12-33: US - Prednisone Cost per Unit & Supply of 5mg/ml Oral Solution (US$), December'2023
Figure 12-34: US - Prednisone Cost per Unit & Supply of 1mg Oral Tablet (US$), December'2023
Figure 12-35: US - Prednisone Cost per Unit & Supply of 2.5mg Oral Tablet (US$), December'2023
Figure 12-36: US - Prednisone Cost per Unit & Supply of 5mg Oral Tablet (US$), December'2023
Figure 12-37: US - Prednisone Cost per Unit & Supply of 50mg Oral Tablet (US$), December'2023
Figure 12-38: US - Prednisone Cost per Unit & Supply of 10mg Oral Tablet (US$), December'2023
Figure 12-39: US - Prednisone Cost per Unit & Supply of 20mg Oral Tablet (US$), December'2023
Figure 12-40: US - Vinblastine Cost per Unit & Supply (US$), December'2023
Figure 12-41: US - Dacarbazine Cost per Unit & Supply for 100mg Intravenous Powder (US$), December'2023
Figure 12-42: US - Dacarbazine Cost per Unit & Supply for 200mg Intravenous Powder (US$), December'2023
Figure 12-43: US - Erbitux Cost per Unit & Supply (US$), December'2023
Figure 12-44: US - Camptosar Cost per Unit & Supply (US$), December'2023
Figure 12-45: US - Irinotecan Cost per Unit & Supply (US$), December'2023
Figure 12-46: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 12-47: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 12-48: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 12-49: US - Adrucil Cost per Unit & Supply (US$), December'2023
Figure 12-50: US - Fluorouracil Cost per Unit & Supply (US$), December'2023
Figure 12-51: US - Leucovorin Cost of Supply of 100mg, 200mg, 350mg & 500mg Injectable Powder (US$), December'2023
Figure 12-52: US - Leucovorin Cost per Unit & Supply of Injectable Solution (US$), December'2023
Figure 12-53: US - Leucovorin Cost per Unit & Supply of 5mg Oral Tablet (US$), December'2023
Figure 12-54: US - Leucovorin Cost per Unit & Supply of 10mg Oral Tablet (US$), December'2023
Figure 12-55: US - Leucovorin Cost per Unit & Supply of 15mg Oral Tablet (US$), December'2023
Figure 12-56: US - Leucovorin Cost per Unit & Supply of 25mg Oral Tablet (US$), December'2023
Figure 12-57: US - Avastin Cost per Unit & Supply (US$), December'2023
Figure 12-58: US - Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$), December'2023
Figure 12-59: US - Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$), December'2023
Figure 12-60: US - Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml & 160ml (US$), December'2023
Figure 12-61: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), December'2023
Figure 12-62: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 12-63: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 12-64: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 12-65: US - Tecentriq Cost per Unit & Supply (US$), November'2023
Figure 12-66: US - Gemzar Cost of Supply (US$), December'2023
Figure 12-67: US - Infugem Cost per Unit & Supply (US$), December'2023
Figure 12-68: US - Hycamtin Cost of Supply of Oral Capsule (US$), December'2023
Figure 12-69: US - Topotecan Cost of Supply of Intravenous Solution (US$), December'2023
Figure 12-70: US - Keytruda Cost per Unit & Supply (US$), November'2023
Figure 12-71: EU - Keytruda Cost of Supply (US$), November'2023
Figure 12-72: US - Xeloda Cost per Unit & Supply (US$), November'2023
Figure 12-73: US - Capecitabine Cost per Unit & Supply of 150mg (US$), November'2023
Figure 12-74: US - Capecitabine Cost per Unit & Supply of 500mg (US$), November'2023
Figure 12-75: US - Adrucil Cost per Unit & Supply (US$), December'2023
Figure 12-76: US - Fluorouracil Cost per Unit & Supply (US$), December'2023
Figure 12-77: US - Cyclophosphamide Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-78: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml, & 500mg/ml (US$), December'2023
Figure 12-79: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Dose 200mg/ml (US$), December'2023
Figure 12-80: US - Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$), December'2023
Figure 12-81: US - Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$), December'2023
Figure 12-82: US - Adriamycin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-83: US - Adriamycin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-84: US - Doxorubicin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-85: US - Doxorubicin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-86: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 12-87: US - Abraxane Cost per Unit & Supply (US$), December'2023
Figure 12-88: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 12-89: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 12-90: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 12-91: US - Eloxatin Cost per Unit & Supply (US$), December'2023
Figure 12-92: US - Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$), December'2023
Figure 12-93: US - Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-94: US - Gemzar Cost of Supply (US$), December'2023
Figure 12-95: US - Infugem Cost per Unit & Supply (US$), December'2023
Figure 12-96: US - Gemcitabine Cost of Supply of Intravenous Powder for Injection (US$), December'2023
Figure 12-97: US - Gemcitabine Cost per Unit & Supply of 38mg/ml Intravenous Solution (US$), December'2023
Figure 12-98: US - Gemcitabine Cost per Unit & Supply of 100mg/ml Intravenous Solution (US$), December'2023
Figure 12-99: US - Alimta Cost of Supply (US$), December'2023
Figure 12-100: US - Pemfexy Cost per Unit & Supply (US$), December'2023
Figure 12-101: US - Pemetrexed Cost per Unit & Supply of Intravenous Powder for Injection (US$), December'2023
Figure 12-102: US - Pemetrexed Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-103: US - Ellence Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-104: US - Epirubicin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-105: US - Herceptin Cost per Unit & Supply (US$), November'2023
Figure 12-106: US - Trastuzumab Biosimilar Cost per Unit & Supply (US$), November'2023
Figure 12-107: US - Xeloda Cost per Unit & Supply (US$), November'2023
Figure 12-108: US - Capecitabine Cost per Unit & Supply of 150mg (US$), November'2023
Figure 12-109: US - Capecitabine Cost per Unit & Supply of 500mg (US$), November'2023
Figure 12-110: US - Adrucil Cost per Unit & Supply (US$), December'2023
Figure 12-111: US - Fluorouracil Cost per Unit & Supply (US$), December'2023
Figure 12-112: US - Cyclophosphamide Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-113: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml & 500mg/ml (US$), December'2023
Figure 12-114: US - Cyclophosphamide Cost per Unit & Supply of Intravenous Solutions of Dose 200mg/ml (US$), December'2023
Figure 12-115: US - Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$), December'2023
Figure 12-116: US - Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$), December'2023
Figure 12-117: US - Adriamycin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-118: US - Adriamycin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-119: US - Doxorubicin Cost of Supply of Intravenous Powder (US$), December'2023
Figure 12-120: US - Doxorubicin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 12-121: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 12-122: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 12-123: US - Libtayo Cost per Unit & Supply (US$), December'2023
Figure 12-124: US - Libtayo Cost per Unit & Supply (US$), December'2023
Figure 12-125: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 12-126: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 12-127: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 12-128: US - Eloxatin Cost per Unit & Supply (US$), December'2023
Figure 12-129: US - Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$), December'2023
Figure 12-130: US - Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 13-1: US - Phesgo Cost per Unit & Supply (US$), December'2023
Figure 13-2: EU - Phesgo Cost per Unit & Supply (US$), December'2023
Figure 13-3: US - Darzalex Cost per Unit & Supply (US$), November'2023
Figure 13-4: EU - Darzalex Cost per Unit & Supply (US$), December'2023
Figure 13-5: US - Kyprolis Cost per Unit & Supply (US$), November'2023
Figure 13-6: US - Dexamethasone Cost per Unit & Supply of 4mg/ml Injectable Solution (US$), December'2023
Figure 13-7: US - Dexamethasone Cost per Unit & Supply of 10mg/ml Injectable Solution (US$), December'2023
Figure 13-8: US - Dexamethasone Cost per Unit & Supply of 10mg/ml Preservative-Free Injectable Solution (US$), December'2023
Figure 13-9: US - Dexamethasone Cost per Unit & Supply of Oral Liquid (US$), December'2023
Figure 13-10: US - Dexamethasone Cost per Unit & 100-Tablet Supply of 0.5mg, 1mg & 6mg Oral Tablets (US$), December'2023
Figure 13-11: US - Dexamethasone Cost per Unit & Supply of 0.75mg Oral Tablets (US$), December'2023
Figure 13-12: US - Dexamethasone Cost per Unit & Supply of 1.5mg Oral Tablets (US$), December'2023
Figure 13-13: US - Dexamethasone Cost per Unit & Supply of 2mg Oral Tablets (US$), December'2023
Figure 13-14: US - Dexamethasone Cost per Unit & Supply of 4mg Oral Tablets (US$), December'2023
Figure 13-15: US - TaperDex Cost per Unit & Supply (US$), December'2023
Figure 13-16: US - Velcade Cost per Supply (US$), November'2023
Figure 13-17: US - Bortezomib Cost of Supply (US$), December'2023
Figure 13-18: US - Thalomid Cost per Unit & Supply of 50mg Capsule (US$), December'2023
Figure 13-19: US - Thalomid Cost per Unit & Supply of 100mg & 150mg Capsules (US$), December'2023
Figure 13-20: US - Revlimid Cost per Unit & Supply (US$), December'2023
Figure 13-21: US - Pomalyst Cost per Unit & Supply (US$), December'2023
Figure 13-22: US - Evomela & Generic Melphalan Cost of Supply (US$), December'2023
Figure 13-23: US - Prednisone Cost per Unit & Supply of 1mg/ml Oral Solution (US$), December'2023
Figure 13-24: US - Prednisone Cost per Unit & Supply of 5mg/ml Oral Solution (US$), December'2023
Figure 13-25: US - Prednisone Cost per Unit & Supply of 1mg Oral Tablet (US$), December'2023
Figure 13-26: US - Prednisone Cost per Unit & Supply of 2.5mg Oral Tablet (US$), December'2023
Figure 13-27: US - Prednisone Cost per Unit & Supply of 5mg Oral Tablet (US$), December'2023
Figure 13-28: US - Prednisone Cost per Unit & Supply of 50mg Oral Tablet (US$), December'2023
Figure 13-29: US - Prednisone Cost per Unit & Supply of 10mg Oral Tablet (US$), December'2023
Figure 13-30: US - Prednisone Cost per Unit & Supply of 20mg Oral Tablet (US$), December'2023
Figure 13-31: US - Empliciti Cost of Supply (US$), November'2023
Figure 13-32: US - Pomalyst Cost per Unit & Supply (US$), December'2023
Figure 13-33: US - Dexamethasone Cost per Unit & Supply of 4mg/ml Injectable Solution (US$), December'2023
Figure 13-34: US - Dexamethasone Cost per Unit & Supply of 10mg/ml Injectable Solution (US$), December'2023
Figure 13-35: US - Dexamethasone Cost per Unit & Supply of 10mg/ml Preservative-Free Injectable Solution (US$), December'2023
Figure 13-36: US - Dexamethasone Cost per Unit & Supply of Oral Liquid (US$), December'2023
Figure 13-37: US - Dexamethasone Cost per Unit & 100-Tablet Supply of 0.5mg, 1mg, & 6mg Oral Tablets (US$), December'2023
Figure 13-38: US - Dexamethasone Cost per Unit & Supply of 0.75mg Oral Tablets (US$), December'2023
Figure 13-39: US - Dexamethasone Cost per Unit & Supply of 1.5mg Oral Tablets (US$), December'2023
Figure 13-40: US - Dexamethasone Cost per Unit & Supply of 2mg Oral Tablets (US$), December'2023
Figure 13-41: US - Dexamethasone Cost per Unit & Supply of 4mg Oral Tablets (US$), December'2023
Figure 13-42: US - TaperDex Cost per Unit & Supply (US$), December'2023
Figure 13-43: US - Keytruda Cost per Unit & Supply (US$), December'2023
Figure 13-44: EU - Keytruda Cost of Supply (US$), December'2023
Figure 13-45: US - Herceptin Cost per Unit & Supply (US$), November'2023
Figure 13-46: US - Trastuzumab Biosimilar Cost per Unit & Supply (US$), November'2023
Figure 13-47: US - Avastin Cost per Unit & Supply (US$), December'2023
Figure 13-48: US - Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$), December'2023
Figure 13-49: US - Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$), December'2023
Figure 13-50: US - Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml & 160ml (US$), December'2023
Figure 13-51: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), December'2023
Figure 13-52: US - Paclitaxel Cost per Unit & Supply (US$), December'2023
Figure 13-53: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 13-54: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 13-55: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 13-56: US - Xeloda Cost per Unit & Supply (US$), November'2023
Figure 13-57: US - Capecitabine Cost per Unit & Supply of 150mg (US$), November'2023
Figure 13-58: US - Capecitabine Cost per Unit & Supply of 500mg (US$), November'2023
Figure 13-59: US - Adrucil Cost per Unit & Supply (US$), December'2023
Figure 13-60: US - Fluorouracil Cost per Unit & Supply (US$), December'2023
Figure 13-61: US - Cisplatin Cost per Unit & Supply for Intravenous Solution (US$), December'2023
Figure 13-62: US - Paraplatin Cost per Unit & Supply (US$), December'2023
Figure 13-63: US - Carboplatin Cost per Unit & Supply (US$), December'2023
Figure 13-64: US - Eloxatin Cost per Unit & Supply (US$), December'2023
Figure 13-65: US - Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$), December'2023
Figure 13-66: US - Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$), December'2023
Figure 13-67: US - Sarclisa Cost per Unit & Supply (US$), December'2023
Figure 13-68: US - Kyprolis Cost per Unit & Supply (US$), December'2023
Figure 13-69: EU - Sarclisa Cost per Unit & Supply (US$), December'2023
Figure 13-70: US - Pomalyst Cost per Unit & Supply (US$), December'2023

List of Tables

Table 1-1: Global - Approved Cancer Antibody Combinations
Table 9-1: Opdivo & Yervoy Combination - Recommended Dosages
Table 9-2: Imjudo & Imfinzi - Recommended Dosage Schedule for Treatment of NSCLC
Table 10-1: Dose of Gazyva to be Administered During Six 28-Day Treatment Cycles for Patients with CLL
Table 10-2: Cabometyx & Nivolumab - Recommended Dosage of Combination
Table 11-1: Monjuvi - Dosing Schedule
Table 12-1: Jemperli - Recommended Dosage
Table 12-2: US - Approved Cyramza-Chemotherapy Combinations
Table 12-3: US - Approved Vectibix-Chemotherapy Combinations
Table 12-4: US - Approved Adcetris-Chemotherapy Combinations
Table 12-5: Adcetris - Recommended Dosage
Table 12-6: US - Approved Erbitux-Chemotherapy Combinations
Table 12-7: US - Approved Avastin-Chemotherapy Combinations
Table 12-8: US - Approved Keytruda-Chemotherapy Combinations
Table 12-9: Keytruda - Recommended Doses
Table 12-10: US - Approved Herceptin-Chemotherapy Combinations
Table 13-1: Phesgo: Recommended Dosage & Administration Schedule
Table 13-2: US - Approved Darzalex-Chemotherapy Combinations
Table 13-3: Darzalex - Dosing Schedule in Combination with Lenalidomide or Pomalidomide (4-Week Cycle) & Low-Dose Dexamethasone
Table 13-4: Darzalex - Dosing Schedule in Combination with Bortezomib, & Prednisone ([VMP], 6-Week Cycle)
Table 13-5: Darzalex - Dosing Schedule in Combination with Bortezomib, Thalidomide & Dexamethasone ([VTd]; 4-Week Cycle)
Table 13-6: Darzalex - Dosing Schedule with Bortezomib & Dexamethasone (3-Week Cycle)
Table 13-7: Darzalex - Dosing Schedule with Bortezomib & Dexamethasone (3-Week Cycle)
Table 13-8: Empliciti - Recommended Dosing Schedule in Combination with Lenalidomide & Dexamethasone
Table 13-9: Empliciti - Recommended Dosing Schedule in Combination with Pomalidomide & Dexamethasone
Table 13-10: US - Approved Keytruda-Chemotherapy Combinations
Table 13-11: Keytruda - Recommended Dosage
Table 13-12: US - Approved Sarclisa-Chemotherapy Combinations
Table 13-13: Sarclisa - Dosing Schedule in Combination with Pomalidomide & Dexamethasone or in Combination with Carfilzomib & Dexamethasone